Literature DB >> 12455292

Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature.

Alejandro Rodríguez1, Jean-Jacques Patard, Bernard Lobel.   

Abstract

OBJECTIVE: To study the incidence, clinical presentation and pathological prognostic factors affecting disease outcome of RCC in young adults less than 40 years old.
METHODS: The charts o medical records of 400 patients treated surgically for RCC between January 1984 and December 1999 were reviewed. 29 (7.25%) patients were under 40. We used ANOVA regression and Chisquare (Fisher exact test) to assess the prognostic value of the quantitative and qualitative variables, respectively. Estimation of the survival distributions were calculated according to Kaplan-Meier method and compared with Log rank test. Multivariate analysis of the entire population utilizing Cox models was performed.
RESULTS: The most common histological cell type was clear cell carcinoma, found in 20 (69%) patients. At a median follow-up of 80 months, 20 (69%) patients were disease free and 9 (31%) died of the disease. Incidental discovery (p = 0.05), tumor stage (p = 0.043), grade (p = 0.011), lymphatic invasion (p < 0.0001) metastasis (p = 0.003), adrenal invasion (p = 0.024), and renal vein invasion (p < 0.0001) were associated with prognosis (Kaplan-Meier). When comparing patients less than 40 years vs. older than 40 years, we found significant differences in histology type (clear cell carcinoma 69% vs. 91%; p = 0.0001), and tumor stage at presentation (pT2 = 34.5% vs. 17.3%; p = 0.04) (pT3 = 20.7% vs. 42%; p = 0.03). Disease free survival was not significantly different between the two groups (69% vs. 65.7%; Log rank test p = 0.4).
CONCLUSION: Although rare, RCC in young adults seems to follow a course similar to the disease seen in older patients. Among the prognostic factors studied incidental discovery, pathological stage of the tumor and grade, were associated with survival. Stage at presentation was different between the two populations however survival was not affected by age.

Entities:  

Mesh:

Year:  2002        PMID: 12455292

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  7 in total

Review 1.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

2.  Renal cell carcinoma: Are we attacking a different tumor over the past 10 years?

Authors:  Ahmed Fouad Kotb; Doaa Attia; Mohamed Mohie Hashad; Tamer Mohammed Abou Youssif; Nora Abdelkawy; Asmaa Ismail; Ahmed Elabbady; Mohamed Adel Atta
Journal:  Int J Health Sci (Qassim)       Date:  2016-04

3.  Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients.

Authors:  Jae Hee Suh; Tina Oak; Jae Y Ro; Luan D Truong; Alberto G Ayala; Steven S Shen
Journal:  Int J Clin Exp Pathol       Date:  2009-01-30

4.  The relationship between histopathology and age factor in patients who were operated for renal masses.

Authors:  Taha Numan Yıkılmaz; Okan Baş; Ali İhsan Arık; Fatih Hızlı; Halil Başar
Journal:  Turk J Urol       Date:  2015-06

5.  Renal cell carcinoma in young and old patients--is there a difference?

Authors:  R Houston Thompson; Maria A Ordonez; Alexia Iasonos; Fernando P Secin; Bertrand Guillonneau; Paul Russo; Karim Touijer
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

6.  Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.

Authors:  Sumanta K Pal; JoAnn Hsu; Sarah Hsu; Jensen Hu; Paulo Bergerot; Courtney Carmichael; Junmi Saikia; Xueli Liu; Clayton Lau; Przemyslaw Twardowski; Robert A Figlin; Bertram F Yuh
Journal:  J Geriatr Oncol       Date:  2013-04       Impact factor: 3.599

7.  Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates?

Authors:  Stefan Denzinger; Wolfgang Otto; Maximilian Burger; Christine Hammerschmied; Kerstin Junker; Arndt Hartmann; Wolf F Wieland; Bernhard Walter
Journal:  World J Surg Oncol       Date:  2007-02-05       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.